Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum—Insights From a 7‐Year Cohort Study
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/2672157 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Breast Journal, online erschienen am 23.03.2026. Verfasst von Mina AkbariRad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir. Hauptthemen laut MEDLINE: Granulomatous Mastitis, Erythema Nodosum, Hyperprolactinemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
This study presents our observations on the management and follow‐up of patients diagnosed with lobular granulomatous mastitis (LGM) in a cohort study. Additionally, characteristics associated with a longer disease course, as well as treatment challenges in patients with erythema nodosum, diabetes, and hyperprolactinemia, would be discussed.
Methods
From 2015 to 2021, a total of 246 consecutive LGM patients referred to the internal medicine clinic of Ghaem teaching hospital, Mashhad, Iran, were enrolled. Regular assessments were conducted every 3 months until complete symptom resolution. Treatment responses were categorized into five groups: complete resolution, incomplete resolution, resolution with subsequent relapse, no significant improvement, and treatment cessation, with all data meticulously recorded. Telephone follow‐ups were conducted with all patients at the end of the study in December 2022.
Results
A total of 156 episodes were analyzed. Prednisone was administered to 136 patients, while oral methotrexate (MTX) was prescribed to 48 cases. The median age of the cohort was 33 years (interquartile range [IQR], 29–38). Of those on prednisone, 57 (41.9%) achieved complete resolution, with 15 (11%) experiencing subsequent relapse, 33 (24.3%) showing no significant improvement, and 31 (19.9%) discontinuing treatment. Among the MTX recipients, 23 (47.9%) achieved complete resolution, while one showed incomplete resolution. Over the median follow‐up of five years (IQR, 4–6), 139 (89.1%) reported complete resolution, nine (5.8%) showed incomplete resolution, and 8 (5.1%) remained symptomatic. The median disease duration was 18 months (IQR, 7–36). Abscess formation during treatment correlated with prolonged disease duration ( p < 0.04), and higher plasma prolactin levels were associated with extended disease duration ( p = 0.001). However, the disease course did not significantly differ in diabetic cases or those with erythema nodosum compared to others.
Conclusions
Although more than half of LGM patients experienced no significant improvement, recurrence, or discontinued treatment on prednisone or MTX, however, over a median follow‐up of 5 years, approximately 90% of LGM patients achieved complete resolution within a median course of 18 months. The presence of abscesses during treatment and elevated plasma prolactin levels was linked to longer disease duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
- Department of Infectious and Tropical Diseases, School of Medicine, Islamic Azad University, Mashhad Branch, Mashhad, Iran, azad.ac.ir.
- Department of Hematology and Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, mums.ac.ir.
ORCID-Profile: Mina AkbariRad, Fereshte Sheybani, Abdollah Firoozi, Samaneh Sajjadi, Maryam Emadzadeh, Marzieh Kazerani, Sajad Ataei Azimi, Mahdieh Mottaghi
Zitieren
APA
AkbariRad, M., Sheybani, F., Firoozi, A., Sajjadi, S., Emadzadeh, M., Kazerani, M., Ataei Azimi, S., & Mottaghi, M. (2026). Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum—Insights From a 7‐Year Cohort Study. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/2672157
Vancouver
AkbariRad M, Sheybani F, Firoozi A, Sajjadi S, Emadzadeh M, Kazerani M, et al. Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum—Insights From a 7‐Year Cohort Study. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/2672157
BibTeX
@article{AkbariRad2026,
author = {AkbariRad, Mina and Sheybani, Fereshte and Firoozi, Abdollah and Sajjadi, Samaneh and Emadzadeh, Maryam and Kazerani, Marzieh and Ataei Azimi, Sajad and Mottaghi, Mahdieh},
title = {Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum—Insights From a 7‐Year Cohort Study},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/2672157}
}
EUVIMED